Preliminary Experimental Study on Key Technologies for Early Screening of Gastric Cancer

Launched by ZHEJIANG CANCER HOSPITAL · Aug 7, 2023

Keywords

ClinConnect Summary

This clinical trial is exploring new ways to detect gastric cancer early by studying blood samples from both gastric cancer patients and healthy individuals. Researchers will analyze the blood for specific markers related to cancer, such as DNA and proteins, to understand how they differ between those with the disease and those without. The goal is to create a new diagnostic model that can help identify gastric cancer more accurately.

To participate, individuals must be between 18 and 100 years old and have been diagnosed with Stage I-III gastric cancer, without having received any treatment prior to the blood draw. The study aims to recruit a total of 700 patients from Zhejiang Cancer Hospital, along with additional participants from other hospitals. Each participant will provide a small amount of blood, which will be used for various tests. It's important to know that some people may not be eligible due to other health conditions or recent medical treatments. Overall, this trial hopes to improve early detection of gastric cancer, which can lead to better treatment outcomes.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age between 18 and 100 years.
• • ECOG performance status of 0 or 1.
• • Pathologically confirmed Stage I-III gastric cancer patients.
• • Patients who have not undergone any anti-tumor treatment (including chemotherapy, radiotherapy, targeted therapy, surgery, anesthesia, etc.) before blood collection.
• • Subjects and their family members who can comprehend the research protocol and are willing to participate in the study, providing written informed consent.
• Exclusion Criteria:
• • Presence of other hereditary diseases or other tumors.
• • Severe inflammatory reactions caused by acute illnesses within 14 days prior to blood draw or use of steroids.
• • Previous organ transplantation, stem cell transplantation, bone marrow transplantation, or blood transfusion within the last month before enrollment.
• • Pregnant women.
• • Participation in other clinical trials requiring medication intake within the last 60 days (including anesthesia).
• • Severe cardiovascular diseases, uncontrolled infections, or other uncontrollable comorbidities.
• • Subjects or family members unable to comprehend the conditions and objectives of the study.